Sponsor:
Indaptus Therapeutics, Inc
Code:
NCT05651022
Conditions
Solid Tumor, Adult
HCC - Hepatocellular Carcinoma
CRC (Colorectal Cancer)
Pancreatic Adenocarcinoma
NSCLC Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Decoy20
Tislelizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-01. This information was provided to ClinicalTrials.gov by Indaptus Therapeutics, Inc on 2025-04-04.